Rudolph Valentino's Isotta Fraschini Awarded Best in Show at the Lugano Elegance Concours d'Elegance 2024
mehr
Storys aus Lugano/Switzerland
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
ENG - Temera, Luxochain & Polygon, announce the collaboration with Bulgari for the launch of the new Octo Finissimo Ultra
Lugano, Switzerland (ots/PRNewswire) - Temera, Luxochain and Polygon are pleased to announce their role as partners for the launch project of the new model Octo Finissimo Ultra, available in a limited edition of only 10 pieces. Bulgari with this initiative masters again its leadership as innovator in the hard luxury ...
mehrLugano NFT Week: Lugano is becoming a Blockchain & Crypto-Friendly City
Lugano, Switzerland (ots/PRNewswire) - From 15-21 November Lugano Living Lab, the digital innovation laboratory of the City of Lugano, has promoted an unprecedented exhibition that explores the fascinating world of NFT and Crypto Art with an exhibition, events and dedicated workshops. Lugano is increasingly a Blockchain & Crypto-Friendly City. After the launch at the ...
mehrLugano NFT Week: Lugano is becoming a Blockchain & Crypto-Friendly City
Lugano, Switzerland (ots/PRNewswire) - From 15-21 November Lugano Living Lab, the digital innovation laboratory of the City of Lugano, has promoted an unprecedented exhibition that explores the fascinating world of NFT and Crypto Art with an exhibition, events and dedicated workshops. Lugano is increasingly a Blockchain & Crypto-Friendly City. After the launch at the ...
mehrLugano NFT Week: Lugano is becoming a Blockchain & Crypto-Friendly City.
Lugano, Switzerland (ots/PRNewswire) - From 15-21 November Lugano Living Lab, the digital innovation laboratory of the City of Lugano, promotes an unprecedented exhibition that explores the fascinating world of NFT and Crypto Art with an exhibition, events and dedicated workshops. An unmissable opportunity to look into this new sector of digital art, discover ...
mehrHelsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
Lugano, Switzerland and San Diego (ots/PRNewswire) - Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016 Global Phase 3 study site recruitment is ongoing Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, ...
mehrHelsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting
Lugano, Switzerland and San Diego (ots/PRNewswire) - Data to be presented on December 3, 2016; Abstract now available online Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel ...
mehrHelsinn Group Introduces Helsinn Investment Fund
Lugano, Switzerland (ots/PRNewswire) - ~ Helsinn Group creates new investment fund in 40th anniversary year ~ ~ The new fund will focus on supporting early-stage investment opportunities in areas of high unmet patient need ~ Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, today introduces Helsinn Investment Fund S.A. ("the Fund"), a fund focused on early-stage investment opportunities in ...
mehrHelsinn Celebrates its 40th Anniversary
Lugano, Switzerland (ots/PRNewswire) - ~ 40 years helping patients achieve a better quality of life ~ Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is delighted to launch its 40th anniversary celebrations in San Francisco, US, at the time of the JP Morgan 34th Annual Healthcare Conference. Helsinn believes its core values of respect, integrity and quality have underpinned four decades of ...
mehrEuropean Society for Medical Oncology (ESMO)
ESMO announces annual medical oncology congress platform in Europe from 2016
Lugano, Switzerland (ots) - The European Society for Medical Oncology, the pan-European association representing medical oncologists in Europe and beyond, has announced that it will be organising an annual Congress in Europe from 2016. A record 19,809 participants from 134 countries gathered at ESMO 2014 in Madrid to hear the results of trials which included ...
mehrEisai Oncology & Helsinn Group to Present New CINV Research at 2014 International Symposium on Supportive Care in Cancer
Woodcliff Lake, NJ, and Lugano, Switzerland (ots) - Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed- dose combination of netupitant and palonosetron being evaluated for the prevention of chemotherapy-induced nausea and vomiting ...
mehrHelsinn Therapeutics (U.S.), Inc. Strengthens its Board of Directors
Lugano, Switzerland (ots) - Helsinn Group, the Company focused on building quality cancer care, announced today the appointment of Dr. Philip S. Schein, to the Board of Directors of its U.S. subsidiary, Helsinn Therapeutics Inc. ("HTU"), effective 8 May 2014. Dr. Philip Schein was the former Founder, Chairman and CEO of US Biosciences, Inc., and Chair of the Clinical Investigations Committee of the National Cancer ...
mehrHelsinn promotes the use of mobile technology in cancer supportive care through mobile health
Lugano, Switzerland (ots) - The pharmaceutical group in Ticino, global leader in cancer supportive care, supports the International Conference on mobile technology dedicated to improve the quality of life of people with cancer in collaboration with SDA Bocconi and CERGAS Bocconi. The combination of medicine and mobile technology to improve the quality of life of people ...
mehrHelsinn announces European Medicines Agency acceptance of regulatory submission for netupitant-palonosetron fixed dose combination (NEPA)
Lugano, Switzerland (ots) - NEPA is currently under development for the treatment of chemotherapy-induced nausea and vomiting The Swiss pharmaceutical Helsinn Group announced today that on January 22nd the European Medicines Agency (EMA) determined netupitant-palonosetron fixed dose combination (NEPA) Marketing ...
mehrSwiss-based Helsinn Group and Mundipharma sign for rights to Phase III Netupitant-Palonosetron fixed dose combination for China
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
mehrSwiss-based Helsinn Group and Mundipharma sign for rights to Phase III Netupitant-Palonosetron fixed dose combination for China
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
mehrHelsinn and Italfarmaco reinforce their alliance through the grant of rights to phase-III ghrelin receptor agonist Anamorelin in Italy
Lugano, Switzerland (ots) - Helsinn Group grants exclusive distribution and licensing rights to Italfarmaco for the commercialization of its compound currently in development for the treatment of anorexia-cachexia syndrome related to non-small cell lung cancer (NSCLC) Helsinn Group is pleased to announce that ...
mehrHelsinn Group and Eisai announce FDA acceptance of New Drug Application for investigational compound netupitant 300 mg + palonosetron 0.50 mg (NEPA)
Lugano, Switzerland/Woodcliff Lake, NJ, USA (ots) - Seeking indication for prevention of chemotherapy-induced nausea and vomiting Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the submission of the New Drug Application (NDA) for the investigational ...
mehrHelsinn Group's representative office in China: Official inauguration
Lugano, Switzerland - Beijing, PRC (ots) - Helsinn Group, the independent, privately-owned, Swiss pharmaceutical company, with a worldwide presence built over 35 years, lands in China. Helsinn's Representative Office was officially inaugurated in Beijing, PRC yesterday. With headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United ...
mehrHelsinn and Chugai Pharma Marketing enter into agreement for rights of Anamorelin,currently in development for treatment of anorexia-cachexia syndrome related to non-small cell lung cancer in top EU markets
Lugano, Switzerland (ots) - Swiss Pharma Group Helsinn seals an alliance with Japanese company Chugai by granting exclusive distribution & licensing rights to commercialize its innovative phase III ghrelin receptor agonist in Germany, France, Benelux, UK and Ireland Swiss-based Helsinn group has granted Chugai ...
mehrHelsinn to launch sales organization in the United States
Lugano, Switzerland (ots) - The Swiss Helsinn Group announced today the formation of a sales organization in the US subsidiary, Helsinn Therapeutics (US) Inc. A commercial organization of 20 people has been engaged throughout the United States. The new oncology sales representatives will be working via a co-detailing agreement for Aloxi® (palonosetron HCl injection), licensed by the Helsinn Group to Eisai, Inc. The ...
mehrMESA Medical Equipment Solutions and Applications
MESA makes strategic investment in MVS Poland to advance Pan-European multi-vendor offering for diagnostic imaging service, equipment and parts
Lugano, Switzerland and Mikolow, Poland (ots) - Culminating from a three-year relationship involving operational synergies for diagnostic imaging service and equipment solutions, two of the largest multi-vendor service providers in Europe: Pan-European, Swiss-based Medical Equipment Solutions and Applications (MESA) ...
mehrHelsinn and Advancell sign a partnering agreement for ATH008, a new compound for chemotherapy-induced dermatological injuries
Lugano, Switzerland and Barcelona, Spain (ots) - The Swiss pharmaceutical group Helsinn and the Spanish company, Advancell, Advanced In Vitro Cell Technologies, SA, today announced a partnering agreement for the development and worldwide commercialization of ATH008, a new topical product for the prevention and/or ...
mehrHelsinn and Zealand announce Helsinn's decision to advance the development of elsiglutide into Phase IIb for the prevention of chemotherapy-induced diarrhea
Lugano, Switzerland & Copenhagen, Denmark (ots) - The decision follows promising findings from a Phase IIa Proof-of-Concept study. Helsinn is planning a Phase IIb study with elsiglutide, and study activities are expected to start in H2 2013. The Swiss pharmaceutical group Helsinn, a leading player in the cancer ...
mehrHelsinn and Eisai Inc. Announce Top-Line Results for Pivotal Studies of the Investigational Fixed-Dose Combination of Netupitant and Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and ...
mehrHelsinn and DARA Announce U.S. Launch of Gelclair®, an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis
Lugano, Switzerland/Raleigh, N.C. (ots) - The Swiss pharmaceutical Helsinn Group, a leading player in the cancer supportive care arena, announced today that DARA BioSciences, Inc., a U.S. specialty pharmaceutical company focused on oncology and oncology supportive care products, has launched Gelclair® into the U.S. ...
mehrHelsinn Group enters into a new partnership with Healthcare Businesswomen's Association (HBA)
Lugano, Switzerland (ots) - Helsinn Group has entered into a new partnership with Healthcare Businesswomen's Association (HBA). HBA is the premier catalyst for the leadership development of women, to further the advancement and impact of women in healthcare worldwide. HBA accomplishes this by providing educational opportunities to develop cutting-edge industry ...
mehrHelsinn grants stendhal rights to Anamorelin, a first-in-class compound to treat cachexia-anorexia related to non-small cell lung cancer (NSCLC)
Lugano, Switzerland and Mexico City, Mexico (ots) - Stendhal strengthens its pipeline of in-licensed specialty drug products by signing a Distribution and License Agreement with Helsinn Group for an innovative phase III ghrelin receptor agonist. Swiss pharmaceutical Helsinn Group has granted Latin American specialty ...
mehrPalonosetron infusion bag launched in Japan
Lugano, Switzerland (ots) - The Swiss pharmaceutical Helsinn Group announces today that Taiho Pharmaceutical Co. Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist (5- HT3 RA) palonosetron, has launched on the national market the 0.75mg infusion bag formulation of palonosetron hydrochloride (Aloxi®). The infusion bag is an additional formulation to the 0.75mg injectable form already marketed ...
mehrPrague: Battleground in the fight against retinal diseases / 12th International AMD and Retina Congress in Prague, 2-3 Nov 2012
Lugano, Switzerland (ots) - ESASO, the European School for Advanced Studies in Ophthalmology, has opened the 12th AMD and Retina Congress in Prague. Following on from the 11th congress in Lisbon, which covered the whole spectrum of retinopathy, this year's meeting in the Czech Republic takes a significant step ...
mehr
12Nächste